Filgrastim

非格司亭

Report date: 2025/02/19 16:42:45

Base Information

Drug NameFilgrastim
Drug Alias NameFilgrastimum (Amgen/Kyowa Hakko Kirin)非拉司亭（Amgen/Kyowa Hakko Kirin）重组人粒细胞刺激因子（Amgen/Kyowa Hakko Kirin）G-CSF (Amgen/Kyowa Hakko Kirin)Recombinant Human Granulocyte Colony-stimulating Factor (Amgen/Kyowa Hakko Kirin) +[20] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionColony stimulating factor 3 receptor agonists
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsUveal melanomaSkin MelanomaIschemic Stroke +[43] 
Global Approved IndicationsNeutropenia
Approved Indications in ChinaNeutropenia
Original Approved Country/TerritoryUnited States
Original Approved Date1991/02/20
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen IncKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Hakko Kirin Co LtdNational Cancer InstituteMenogenix Inc +[7] 
Inactive CompaniesDana-Farber Cancer InstituteAzidus BrasilBeike Biotech India Pvt Ltd +[19] 
Active IndicationsMenopausal symptomsMalnutritionNeutropenia +[11] 
Inactive IndicationsUveal melanomaSkin MelanomaIschemic Stroke +[32] 

Other Information

ATC CodeL03AA02
Related LinksWikipediaDrugBankKEGG